Form 4: Immix Biopharma Director Carey Ng Receives Equity Grant

Director Carey Ng was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.

Summary

• Director Carey Ng received a grant of 6,250 restricted stock units (RSUs) on May 22, 2026.
• The director was also granted 12,500 stock options with an exercise price of $8.78 per share.
• The RSUs vest on the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting.
• The stock options vest in equal monthly installments over 12 months, subject to continued board service.
• Following these transactions, the director directly owns 26,250 shares and maintains indirect interest in 1,025,221 shares via Mesa Verde Venture Partners III, LP.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key board leadership through structured vesting schedules.

Negatives

• Minor dilution of existing shareholders due to the issuance of new equity awards.

Risks

• Vesting is contingent upon continued service, creating potential turnover risk if the director departs.
• Market volatility could impact the value of the granted options, which have an exercise price of $8.78.

Future Outlook

The equity grants are subject to continued service on the Board of Directors, with full vesting expected by the 2027 Annual Meeting or the one-year anniversary of the grant.

Management Comments

• The reporting person disclaims beneficial ownership of securities held by Mesa Verde Venture Partners III, LP, except to the extent of his pecuniary interest.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a 12-month vesting schedule for director equity is consistent with standard corporate governance practices for small-cap biotech firms.
• The combination of RSUs and stock options is a common compensation structure used to balance retention and performance incentives.

Related Party Transactions

• The reporting person is the Managing Director of Mesa Verde Venture Partners III, LP, which holds 1,025,221 shares of the issuer.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.
• The grant reinforces the commitment of the director to the company's long-term governance.

Next Steps

• Vesting of RSUs on the earlier of May 22, 2027, or the 2027 Annual Meeting.
• Monthly vesting of stock options over the next 12 months.

Key Dates

Keywords

Immix Biopharma, IMMX, Form 4, Insider Trading, Equity Compensation, Director Compensation, Biotech